Wuhan Keqian Biology Co.,Ltd (SHA:688526)
China · Delayed Price · Currency is CNY 12.38
+0.29 (2.40%)
Jun 23, 2026, 3:00 PM CST
SHA:688526 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 918 | 935.65 | 933.04 | 1,027 | 974.14 | 1,083 |
Other Revenue | 14.09 | 14.09 | 8.88 | 37.14 | 27.12 | 19.86 |
| 932.09 | 949.74 | 941.92 | 1,064 | 1,001 | 1,103 | |
Revenue Growth (YoY) | -5.10% | 0.83% | -11.48% | 6.27% | -9.22% | 30.81% |
Cost of Revenue | 328.96 | 330.72 | 360.45 | 321.43 | 279.05 | 230.42 |
Gross Profit | 603.13 | 619.03 | 581.48 | 742.65 | 722.22 | 872.6 |
Selling, General & Admin | 154.26 | 160.28 | 169.4 | 213.2 | 219.26 | 201.91 |
Research & Development | 100.18 | 96.41 | 86.12 | 88.51 | 102.75 | 80 |
Other Operating Expenses | -1.15 | 1.28 | -0.93 | -0.82 | 6.29 | 5.92 |
Operating Expenses | 259.5 | 247.8 | 266.47 | 385.36 | 339.01 | 296.9 |
Operating Income | 343.63 | 371.23 | 315.01 | 357.29 | 383.21 | 575.71 |
Interest Expense | - | - | -4.77 | -8.16 | -5.45 | -1.81 |
Interest & Investment Income | 59.62 | 63.83 | 73.17 | 94.12 | 75.69 | 71.86 |
Currency Exchange Gain (Loss) | -0.89 | -0.89 | 0 | 0.05 | - | - |
Other Non Operating Income (Expenses) | 1.92 | 1.15 | -0.72 | -0.21 | -0.2 | -0.27 |
EBT Excluding Unusual Items | 404.28 | 435.31 | 382.69 | 443.1 | 453.25 | 645.48 |
Impairment of Goodwill | - | - | -3.31 | - | - | - |
Gain (Loss) on Sale of Investments | 31 | 33.27 | 30.99 | -10.19 | 1.44 | - |
Gain (Loss) on Sale of Assets | -0.05 | - | 0.93 | - | - | - |
Asset Writedown | -3.27 | -1.28 | -0.86 | -1.72 | -0.14 | -1.57 |
Legal Settlements | - | - | - | - | - | 0.82 |
Other Unusual Items | 14.19 | 14.24 | 27.7 | 26.39 | 12.06 | 15.32 |
Pretax Income | 446.15 | 481.54 | 438.13 | 457.58 | 466.61 | 660.05 |
Income Tax Expense | 58.31 | 64.6 | 56.64 | 62 | 57.46 | 89.41 |
Earnings From Continuing Operations | 387.84 | 416.94 | 381.49 | 395.58 | 409.15 | 570.64 |
Minority Interest in Earnings | 1.88 | 1.78 | 0.86 | 0.35 | 0.37 | 0.11 |
Net Income | 389.72 | 418.72 | 382.35 | 395.93 | 409.52 | 570.74 |
Net Income to Common | 389.72 | 418.72 | 382.35 | 395.93 | 409.52 | 570.74 |
Net Income Growth | -3.38% | 9.51% | -3.43% | -3.32% | -28.25% | 27.45% |
Shares Outstanding (Basic) | 464 | 465 | 466 | 466 | 465 | 464 |
Shares Outstanding (Diluted) | 464 | 465 | 466 | 466 | 465 | 464 |
Shares Change (YoY) | 0.29% | -0.22% | 0.10% | 0.10% | 0.29% | 20.20% |
EPS (Basic) | 0.84 | 0.90 | 0.82 | 0.85 | 0.88 | 1.23 |
EPS (Diluted) | 0.84 | 0.90 | 0.82 | 0.85 | 0.88 | 1.23 |
EPS Growth | -3.66% | 9.76% | -3.53% | -3.41% | -28.46% | 6.03% |
Free Cash Flow | 259.74 | 344.66 | 285.74 | 433.53 | 320.86 | 156.82 |
Free Cash Flow Per Share | 0.56 | 0.74 | 0.61 | 0.93 | 0.69 | 0.34 |
Dividend Per Share | 0.640 | 0.640 | 0.430 | 0.430 | 0.190 | 0.190 |
Dividend Growth | 48.84% | 48.84% | - | 126.32% | - | -34.48% |
Gross Margin | 64.71% | 65.18% | 61.73% | 69.79% | 72.13% | 79.11% |
Operating Margin | 36.87% | 39.09% | 33.44% | 33.58% | 38.27% | 52.19% |
Profit Margin | 41.81% | 44.09% | 40.59% | 37.21% | 40.90% | 51.74% |
Free Cash Flow Margin | 27.87% | 36.29% | 30.34% | 40.74% | 32.05% | 14.22% |
EBITDA | 456.28 | 482.99 | 423.23 | 470.54 | 480.16 | 638.35 |
EBITDA Margin | 48.95% | 50.85% | 44.93% | 44.22% | 47.95% | 57.87% |
D&A For EBITDA | 112.65 | 111.76 | 108.22 | 113.24 | 96.95 | 62.64 |
EBIT | 343.63 | 371.23 | 315.01 | 357.29 | 383.21 | 575.71 |
EBIT Margin | 36.87% | 39.09% | 33.44% | 33.58% | 38.27% | 52.19% |
Effective Tax Rate | 13.07% | 13.41% | 12.93% | 13.55% | 12.31% | 13.55% |
Revenue as Reported | 932.09 | 949.74 | 941.92 | 1,064 | 1,001 | 1,103 |
Advertising Expenses | - | 25.46 | 25.7 | 34.1 | 2.87 | 2.96 |